Lopressor/overdosage: Difference between revisions

Jump to navigation Jump to search
Line 17: Line 17:
There is no specific antidote.
There is no specific antidote.


In general, patients with acute or recent [[myocardial infarction]] may be more hemodynamically unstable than other patients and should be treated accordingly ''(see [[Lopressor warnings and precautions#myocaridal Infarction|WARNINGS, Myocardial Infarction]])''.
In general, patients with acute or recent [[myocardial infarction]] may be more hemodynamically unstable than other patients and should be treated accordingly ''(see [[Lopressor warnings and precautions#Myocaridal Infarction|WARNINGS, Myocardial Infarction]])''.


On the basis of the pharmacologic actions of Lopressor, the following general measures should be employed:
On the basis of the pharmacologic actions of Lopressor, the following general measures should be employed:

Revision as of 06:07, 13 March 2014

Metoprolol
Clinical data
Trade namesLopressor, Toprol-xl
AHFS/Drugs.comMonograph
MedlinePlusa682864
[[Regulation of therapeutic goods |Template:Engvar data]]
Pregnancy
category
  • AU: C
  • US: C (Risk not ruled out)
Routes of
administration
Oral, IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability12%
MetabolismHepatic via CYP2D6, CYP3A4
Elimination half-life3-7 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H25NO3
Molar mass267.364 g/mol
3D model (JSmol)
Melting point120 °C (248 °F)
  (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Acute Toxicity

Several cases of overdosage have been reported, some leading to death.

Oral LD 50’s (mg/kg): mice, 1158-2460; rats, 3090-4670.

Signs and Symptoms

Potential signs and symptoms associated with overdosage with Lopressor are bradycardia, hypotension, bronchospasm, myocardial infarction, cardiac failure and death.

Management

There is no specific antidote.

In general, patients with acute or recent myocardial infarction may be more hemodynamically unstable than other patients and should be treated accordingly (see WARNINGS, Myocardial Infarction).

On the basis of the pharmacologic actions of Lopressor, the following general measures should be employed:

Elimination of the Drug: Gastric lavage should be performed.

Other clinical manifestations of overdose should be managed symptomatically based on modern methods of intensive care.

Hypotension: Administer a vasopressor, e.g., levarterenol or dopamine.

Bronchospasm: Administer a beta2-stimulating agent and/or a theophylline derivative.

Cardiac Failure: Administer digitalis glycoside and diuretic. In shock resulting from inadequate cardiac contractility, consider administration of dobutamine, isoproterenol or glucagon.[1]

References

  1. "LOPRESSOR (METOPROLOL TARTRATE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION]".

Adapted from the FDA Package Insert.